New drug cocktail aims to tackle Hard-to-Treat colorectal cancer
NCT ID NCT07011550
First seen Feb 19, 2026 · Last updated May 17, 2026 · Updated 11 times
Summary
This study tested whether a combination of four drugs (BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab) could help control advanced colorectal cancer that has stopped responding to standard treatments. It included 7 adults with a specific type of cancer called microsatellite-stable (MSS) colorectal cancer. The main goal was to check safety and side effects. The study is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STANDARD OF CARE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.